Eli Lilly's Strategic Moves: Beyond the GLP-1 Hype

Eli Lilly faces a critical FDA decision on its oral weight-loss drug Orforglipron amid intense competition from Novo Nordisk and strong financial results.

Eli Lilly is approaching a pivotal quarter, with multiple catalysts on the horizon that could define its trajectory. The pharmaceutical giant is navigating a competitive landscape by focusing on a key regulatory milestone for its oral weight-loss drug while simultaneously expanding its research pipeline far beyond obesity treatments. The central question is whether Lilly can maintain its formidable lead as rivals intensify their efforts.

Financial Momentum and Competitive Pressures

The company enters this critical period from a position of remarkable financial strength. For the full year 2025, Eli Lilly reported revenue of $65.2 billion, a 45% increase, while earnings per share surged 86% to $24.21. This performance was largely fueled by the blockbuster drugs Zepbound and Mounjaro. Zepbound maintained a dominant position in the U.S. prescription obesity drug market, capturing approximately 70% of new prescriptions. Mounjaro secured over 55% of new prescriptions in the U.S. incretin-based type 2 diabetes market. Demonstrating confidence, the board also raised the quarterly dividend to $1.73 per share, up from $1.50, payable on March 10.

However, the competitive environment is tightening significantly. In December 2025, Novo Nordisk received FDA approval for a Wegovy pill (oral semaglutid 25 mg), marking the first oral GLP-1 therapy for weight management, and launched it in the U.S. in early January 2026. This development means Lilly's forthcoming oral candidate must not only demonstrate efficacy but also achieve rapid commercial scaling. Furthermore, the entire GLP-1 sector continues to face pricing pressures. Investor attention is also drawn to Retatrutide, where Phase III TRIUMPH-4 trial data reported weight loss of up to 28.7%.

This competitive tension is reflected in recent market activity. The stock recently closed at €867.10, trading below its 50-day moving average. The 14-day Relative Strength Index (RSI) reading of 28.5 suggests the shares are in significantly oversold territory.

The Orforglipron Catalyst: A Potential Game-Changer

The most immediate driver for the stock is the anticipated FDA decision on Orforglipron, expected in the second quarter of 2026. This once-daily GLP-1 tablet is slated for a U.S. launch for chronic weight management in Q2 2026, pending regulatory clearance. Lilly has filed for approval in more than 40 countries, with an international rollout predominantly expected in 2027.

A significant advantage is that the FDA has granted Orforglipron a "national priority" voucher, which could substantially accelerate the review process and shorten the period of regulatory uncertainty.

Lilly has also taken operational steps to avoid the supply chain issues that plagued earlier GLP-1 drug launches across the industry. According to SEC filings, the company had secured advance inventory worth $1.5 billion as of December 31, mostly dedicated to the GLP-1 pill.

The drug's clinical profile provides additional support. In the 52-week ACHIEVE-3 study involving 1,698 participants across four treatment arms, Orforglipron outperformed oral semaglutid in both A1C reduction and weight loss across all primary and key secondary endpoints. These results were published in The Lancet. Post-approval, U.S. self-pay patients are expected to access the drug via LillyDirect, with the lowest dosage starting at $149.

A Diversifying Pipeline: Expanding the Horizon

Concurrently, Lilly is strategically broadening its research and development efforts. A new Phase 1 study for LY4515100, an oral substance, has been registered. It will initially assess safety and tolerability (single and multiple doses) in healthy volunteers. A protocol update from February 27, 2026, indicates the study is ongoing, with recruitment and fine-tuning continuing.

The company's Alzheimer's program is also expanding geographically. A new study for Remternetug has been registered in China to evaluate the safety, tolerability, and pharmacokinetics of a single dose in healthy Chinese participants. The March 2, 2026, update also points to an active, continually refined study plan during recruitment.

Even within the GLP-1 domain, Lilly is exploring wider applications. The company has cited research into incretin therapies for comorbid conditions such as stress urinary incontinence, peripheral arterial disease, and hypertension. Furthermore, Lilly is investigating combination therapies involving Zepbound for immunology and other indications.

Outlook: Ambitious Targets and Sustained Investment

Looking ahead, Eli Lilly has provided 2026 revenue guidance in the range of $80 to $83 billion. The company also plans to increase R&D expenditures, supported by 36 active Phase 3 programs and additional planned study initiations. The immediate catalyst remains the FDA's decision on Orforglipron in Q2 2026, followed by several upcoming Phase 3 data readouts throughout the year.